4Moving Biotech Raises €12M for OA Drug Development
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
CHICAGO, Feb. 2, 2026 — Northwestern University’s Feinberg School of Medicine has launched the Simpson Querrey Brain Health Institute,...
Middleton, Massachusetts – November 6, 2025 – MavriX Bio, a clinical-stage biotechnology company focused on transformative genetic medicines, announced...
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
October 14, 2025 | Dallas, TX & Aurora, CO — Verily, UCHealth, the University of Colorado Anschutz, and RefinedScience...
